Campbell & CO Investment Adviser LLC Cuts Stake in Vaxcyte, Inc. $PCVX

Campbell & CO Investment Adviser LLC cut its holdings in Vaxcyte, Inc. (NASDAQ:PCVX) by 42.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 42,859 shares of the company’s stock after selling 31,407 shares during the period. Campbell & CO Investment Adviser LLC’s holdings in Vaxcyte were worth $1,544,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of PCVX. CWM LLC grew its stake in shares of Vaxcyte by 197.3% in the second quarter. CWM LLC now owns 1,680 shares of the company’s stock worth $55,000 after purchasing an additional 1,115 shares during the last quarter. Blue Trust Inc. lifted its holdings in Vaxcyte by 176.7% in the 2nd quarter. Blue Trust Inc. now owns 2,161 shares of the company’s stock worth $70,000 after buying an additional 1,380 shares during the period. Virtus Investment Advisers LLC grew its position in shares of Vaxcyte by 45.8% in the 2nd quarter. Virtus Investment Advisers LLC now owns 2,729 shares of the company’s stock worth $89,000 after buying an additional 857 shares during the last quarter. Signaturefd LLC increased its stake in shares of Vaxcyte by 242.3% during the second quarter. Signaturefd LLC now owns 3,266 shares of the company’s stock valued at $106,000 after buying an additional 2,312 shares during the period. Finally, Nisa Investment Advisors LLC raised its holdings in shares of Vaxcyte by 96.3% during the third quarter. Nisa Investment Advisors LLC now owns 3,254 shares of the company’s stock valued at $117,000 after acquiring an additional 1,596 shares in the last quarter. 96.78% of the stock is owned by institutional investors.

Insider Activity at Vaxcyte

In related news, insider Harpreet S. Dhaliwal sold 9,743 shares of the firm’s stock in a transaction that occurred on Wednesday, December 31st. The stock was sold at an average price of $46.69, for a total transaction of $454,900.67. Following the completion of the transaction, the insider owned 23,928 shares of the company’s stock, valued at $1,117,198.32. This trade represents a 28.94% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Elvia Cowan sold 11,623 shares of the business’s stock in a transaction on Tuesday, December 23rd. The stock was sold at an average price of $47.92, for a total value of $556,974.16. Following the completion of the sale, the senior vice president directly owned 14,534 shares in the company, valued at $696,469.28. This trade represents a 44.44% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 3.10% of the stock is currently owned by company insiders.

Vaxcyte Trading Down 3.0%

Shares of PCVX stock opened at $46.59 on Friday. The company’s fifty day moving average price is $46.53 and its 200-day moving average price is $39.63. The stock has a market cap of $6.10 billion, a PE ratio of -9.63 and a beta of 1.34. Vaxcyte, Inc. has a 12 month low of $27.66 and a 12 month high of $93.77.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($1.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.27) by ($0.29). During the same quarter in the prior year, the firm earned ($0.83) EPS. On average, sell-side analysts forecast that Vaxcyte, Inc. will post -4.21 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

PCVX has been the topic of several recent analyst reports. Needham & Company LLC lifted their price target on shares of Vaxcyte from $90.00 to $110.00 and gave the company a “buy” rating in a report on Wednesday, January 7th. BTIG Research reaffirmed a “buy” rating and issued a $85.00 target price on shares of Vaxcyte in a research report on Monday, November 10th. Leerink Partners set a $77.00 price target on shares of Vaxcyte and gave the company an “outperform” rating in a research report on Wednesday, November 19th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Vaxcyte in a research note on Friday, January 9th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $101.17.

About Vaxcyte

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.